Kodiak Sciences Inc (NASDAQ:KOD) — Market Cap & Net Worth
Market Cap & Net Worth: Kodiak Sciences Inc (KOD)
Kodiak Sciences Inc (NASDAQ:KOD) has a market capitalization of $2.06 Billion ($2.06 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6055 globally and #1944 in its home market, demonstrating a -6.56% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kodiak Sciences Inc's stock price $32.77 by its total outstanding shares 62849457 (62.85 Million). Also see Kodiak Sciences Inc total assets for a full breakdown of the balance sheet.
Kodiak Sciences Inc Market Cap History: 2018 to 2026
Kodiak Sciences Inc's market capitalization history from 2018 to 2026. Data shows growth from $446.23 Million to $2.06 Billion (15.86% CAGR). Also see cash efficiency ratio of Kodiak Sciences Inc for how efficiently the company converts equity into cash flow.
Index Memberships
Kodiak Sciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.08% | #169 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #687 of 3165 |
Weight: Kodiak Sciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kodiak Sciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kodiak Sciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Kodiak Sciences Inc (KOD) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of KOD by Market Capitalization
Companies near Kodiak Sciences Inc in the global market cap rankings as of September 18, 2026. Review KOD tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Kodiak Sciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Kodiak Sciences Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Kodiak Sciences Inc's market cap moved from $446.23 Million to $ 2.06 Billion, with a yearly change of 15.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.06 Billion | +17.20% |
| 2025 | $1.76 Billion | +181.01% |
| 2024 | $625.35 Million | +227.30% |
| 2023 | $191.06 Million | -57.54% |
| 2022 | $450.00 Million | -91.55% |
| 2021 | $5.33 Billion | -42.29% |
| 2020 | $9.23 Billion | +104.18% |
| 2019 | $4.52 Billion | +913.38% |
| 2018 | $446.23 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Kodiak Sciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.06 Billion USD |
| MoneyControl | $2.06 Billion USD |
| MarketWatch | $2.06 Billion USD |
| marketcap.company | $2.06 Billion USD |
| Reuters | $2.06 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in… Read more